Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops …
Over the last 12 months, insiders at Aptose Biosciences Inc. have bought $0 and sold $0 worth of Aptose Biosciences Inc. stock.
On average, over the past 5 years, insiders at Aptose Biosciences Inc. have bought $202,140 and sold $1.43M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 17,000 shares for transaction amount of $53,380 was made by Seizinger Bernd R. (director) on 2023‑09‑22.
2023-09-22 | director | 17,000 0.2389% | $3.14 | $53,380 | -46.38% | |||
2022-06-06 | Chair, President & CEO | 10,000 0.0109% | $0.97 | $9,681 | -32.29% | |||
2021-12-20 | director | 10,000 0.0117% | $1.45 | $14,490 | -38.49% | |||
2021-12-16 | director | 100,000 0.1055% | $1.38 | $137,900 | -41.50% | |||
2021-12-16 | Chair, President & CEO | 13,183 0.0153% | $1.52 | $20,038 | -41.50% | |||
2021-12-15 | director | 270,000 0.2989% | $1.17 | $316,340 | -27.73% | |||
2021-12-15 | Chair, President & CEO | 17,822 0.0189% | $1.12 | $19,961 | -27.73% | |||
2021-11-26 | Chair, President & CEO | 8,643 0.0098% | $2.31 | $19,965 | -57.89% | |||
2021-11-19 | Sr. VP, Chief Medical Officer | 10,000 0.0115% | $2.56 | $25,600 | -59.76% | |||
2021-08-05 | Sale | 10 percent owner | 60,000 0.0677% | $2.62 | $157,200 | -51.72% | ||
2021-08-03 | 10 percent owner | 57,199 0.0647% | $2.65 | $151,406 | -51.52% | |||
2021-07-02 | Chair, President & CEO | 6,081 0.0067% | $3.29 | $19,998 | -57.78% | |||
2021-06-22 | Sale | director | 9,600 0.0106% | $3.24 | $31,104 | -55.59% | ||
2021-06-21 | Sale | director | 15,400 0.0174% | $3.35 | $51,590 | -55.56% | ||
2020-12-22 | Sale | director | 20,000 0.0234% | $4.06 | $81,200 | -20.52% | ||
2020-07-10 | Sale | Chair, President & CEO | 168,891 0.1977% | $6.05 | $1.02M | -16.11% | ||
2020-07-10 | Sale | Executive VP & CFO | 126,668 0.1483% | $6.05 | $766,341 | -16.11% | ||
2020-07-10 | Sale | Senior VP, Chief Bus. Officer | 62,835 0.0735% | $6.05 | $380,152 | -16.11% | ||
2020-07-02 | Sale | Senior VP, Chief Bus. Officer | 20,946 0.0238% | $6.34 | $132,793 | -22.08% | ||
2020-06-24 | Sale | director | 17,000 0.0228% | $6.74 | $114,660 | -22.50% |
Wilson Donald R. Jr. | 10 percent owner | 8888275 45.5314% | $0.25 | 1 | 1 | <0.0001% |
PLATZER ERICH | director | 505000 2.5869% | $0.25 | 3 | 1 | <0.0001% |
Rice William G. | Chair, President & CEO | 353252 1.8096% | $0.25 | 9 | 1 | +2.47% |
Chow Gregory K. | Executive VP & CFO | 232846 1.1928% | $0.25 | 2 | 1 | +46.02% |
BURGER DENIS R | director | 31671 0.1622% | $0.25 | 1 | 0 | <0.0001% |
Annandale Capital | $44,000.00 | 0.15 | 26,666 | -64.29% | -$79,201.98 | 0.01 | |
Caldwell Sutter Capital Inc | $153.00 | <0.01 | 92 | 0% | +$0 | <0.0001 |